(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1 Ibrutinib Maʻemaʻe Kūwaena >99.0% (GC)

ʻO ka wehewehe pōkole:

Inoa Kemika: (S)-1-Boc-3-Hydroxypiperidine

CAS: 143900-44-1

Maʻemaʻe Chiral: >99.0% (GC)

Maʻemaʻe Kemika: >99.0% (GC)

ʻAno: ʻO ka pauka keʻokeʻo a i ʻole nā kristal

Kūwaena o Ibrutinib (CAS: 936563-96-1)

ʻO ke kūlana kiʻekiʻe, ka hana kālepa

E-Mail: alvin@ruifuchem.com

E hoʻouna i ka leka uila iā mākou

Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Ibrutinib pili i waena:
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Na Waiwai Kemika:

Inoa Kimia	(S)-1-Boc-3-Hydroxypiperidine
Nā huaʻōlelo like	(S)-1-(tert-Butoxycarbonyl)-3-Hydroxypiperidine;(S)-1-Boc-3-Piperidinol
Helu CAS	143900-44-1
Helu CAT	RF-CC299
Kūlana Kūʻai	I loko o ka waihona, hana hiki ke 20 Tons / mahina
ʻĀpana Molekala	C10H19NO3
Kaumaha Molecular	201.27
Lae hehee	52.0~56.0 ℃
Ka hikiwawe	Hiki ke hoʻoheheʻe ʻia i ka Methanol
Ka Poali Pono [a]20/D	+9.0°~+11.0° (C=1 i loko o Chloroform)
Brand	Kemika Ruifu

Nā kikoʻī:

'ikamu	Nā kikoʻī
Ka nana aku	Pauda keʻokeʻo a i ʻole nā kristal
Maʻemaʻe Chiral	>99.5% (GC)
Maemae Kemika	>99.5% (GC)
Wai (KF)	≤0.50%
Methanol (GC)	≤50ppm
Ethanol (GC)	≤50ppm
DCM (GC)	≤500ppm
3-Hydroxypiperidine	≤0.10%
3-Hydroxypyridine	≤0.20%
1-Boc-3-Piperidone	≤0.10%
1-Boc-4-Hydroxypiperidine	≤0.10%
1.96 RRT	≤0.20%
ʻO nā mea haumia ʻole i hōʻike ʻia	≤0.10%
Kūlana hoʻāʻo	Kūlana ʻoihana
Hoʻohana	Nā Kūwaena Lapaʻau;Huina Kiral

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai.

Pono:

FAQ:

Noi:

(S)-1-Boc-3-Hydroxypiperidine (CAS: 143900-44-1) he mea koʻikoʻi ka waena chiral no ka synthesis o Ibrutinib (CAS: 936563-96-1).ʻO Ibrutinib kahi ʻano o Bruton tyrosine kinase (BTK) inhibitor, hiki ke hoʻohana ʻia no ka mālama ʻana i ka maʻi maʻi lymphocytic leukemia (CLL) a me ka lymphoma cell mantle (MCL).No ka B-cell non-Hodgkin's lymphoma ka MCL a me CLL, he paʻakikī ke ho'ōla a maʻalahi hoʻi e hoʻi hou.ʻAʻole loaʻa i ka immunotherapy kemika maʻamau ka huli ʻana, loaʻa pinepine i 3 a 4 mau hopena ʻino.Hiki i nā lymphocytes Ibrutinib a me B ke hoʻopaʻa i ka BTK pono no ka hoʻokumu ʻana, ka ʻokoʻa, a me ka hoʻouna ʻana i ka ʻike, kaohi ʻana i ka hana BTK me ka hiki ʻole ke hoʻihoʻi hou ʻia, a ke keʻakeʻa i ka hoʻonui ʻana o ka cell tumo a ola pono.Hiki ke hoʻopili koke ʻia ʻo Ibrutinib ma hope o ka hoʻokele waha, i ka wā o 1 ~ 2h hiki ke kiʻekiʻe o ke koko, nā hopena ʻino i hoʻokahi a ʻelua paha, no laila, e lilo ʻo Ibrutinib i koho hou no ka mālama ʻana iā CLL a me MCL.